An application of Longhu Rendan in preparing a medicament for preventing and/or treating liver fibrosis The Longhu Rendan has significant effect in improving liver fibrosis, and its effect in anti-liver fibrosis and liver protection is equivalent to those of a positive drug silybin.

A traditional Chinese medicine composition for infectious disease recovery, containing the Chinese medicinal herbs: 2-4 parts of ginseng, 4-8 parts of Ophiopogon japonicus, 2-4 parts of Schisandra chinensis berry, 6-10 parts of Wolfiporia extensa Ginns, 6-10 parts of rhizoma pinelliae, 4-8 parts of Scrophularia ningpoensis, 4-6 parts of stir-fried Atractylodes, 4-8 parts of mandarin orange peel, 2-4 parts of Glycyrrhiza uralensis, 4-8 parts of Bupleurum scorzonerifolium, 2-4 parts of Actaea cimicifuga, 8-12 parts of Coix lacryma-jobi, 8-12 parts of Scutellaria baicalensis, 8-12 parts of Verbena officinalis, 12-18 parts of rhizoma phragmitis, and 1-3 parts of Lophatherum gracile. The present traditional Chinese medicine composition can be used in medicines for the prevention, treatment, or alleviation of the sequelae or complications of infectious diseases or for the promotion of the functional recovery of damaged tissues, organs or systems caused by infectious diseases.

A traditional Chinese medicine composition for infectious disease recovery, containing the Chinese medicinal herbs: 2-4 parts of ginseng, 4-8 parts of Ophiopogon japonicus, 2-4 parts of Schisandra chinensis berry, 6-10 parts of Wolfiporia extensa Ginns, 6-10 parts of rhizoma pinelliae, 4-8 parts of Scrophularia ningpoensis, 4-6 parts of stir-fried Atractylodes, 4-8 parts of mandarin orange peel, 2-4 parts of Glycyrrhiza uralensis, 4-8 parts of Bupleurum scorzonerifolium, 2-4 parts of Actaea cimicifuga, 8-12 parts of Coix lacryma-jobi, 8-12 parts of Scutellaria baicalensis, 8-12 parts of Verbena officinalis, 12-18 parts of rhizoma phragmitis, and 1-3 parts of Lophatherum gracile. The present traditional Chinese medicine composition can be used in medicines for the prevention, treatment, or alleviation of the sequelae or complications of infectious diseases or for the promotion of the functional recovery of damaged tissues, organs or systems caused by infectious diseases.

The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicaments. In one aspect, the present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. In another aspect, the present disclosure further provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing uric acid nephropathy. Animal experiments have confirmed that the Liriodendron chinense (Hemsl.) Sarg. can significantly reduce the serum uric acid level, and relieve degrees of renal tubular dilation, glomerulosclerosis, and renal interstitial fibrosis of hyperuricemic mice. Further research shows that the Liriodendron chinense (Hemsl.) Sarg. plays a role in reducing the serum uric acid level by promoting renal uric acid excretion. The use of the present disclosure can provide a new medicament choice for clinical treatment of hyperuricemia and hyperuricemic nephropathy caused by the hyperuricemia.

The present disclosure relates to the field of medicaments, and particularly to use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level and preventing and treating uric acid nephropathy, and belongs to the field of medicaments. In one aspect, the present disclosure provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for reducing a serum uric acid level. In another aspect, the present disclosure further provides use of Liriodendron chinense (Hemsl.) Sarg. or an extract thereof in the preparation of a medicament for treating and/or preventing uric acid nephropathy. Animal experiments have confirmed that the Liriodendron chinense (Hemsl.) Sarg. can significantly reduce the serum uric acid level, and relieve degrees of renal tubular dilation, glomerulosclerosis, and renal interstitial fibrosis of hyperuricemic mice. Further research shows that the Liriodendron chinense (Hemsl.) Sarg. plays a role in reducing the serum uric acid level by promoting renal uric acid excretion. The use of the present disclosure can provide a new medicament choice for clinical treatment of hyperuricemia and hyperuricemic nephropathy caused by the hyperuricemia.

Described herein are compositions comprising an active compound from an extract of magnolia, or a derivative thereof; and a non-surfactant electrolyte in an amount effective to stabilize the composition, and methods of making and using the same.

The present invention includes a composition and composition comprising: an extract of Cassytha filiformis, an extract of Cuscuta sandwichiana, or both, adapted for oral administration and in an amount sufficient to induce sleep, improve sleep, or both.

The present invention includes a composition and composition comprising: an extract of Cassytha filiformis, an extract of Cuscuta sandwichiana, or both, adapted for oral administration and in an amount sufficient to induce sleep, improve sleep, or both.

Described herein are compositions and methods of treatment for musculoskeletal pain.

Described herein are compositions and methods of treatment for musculoskeletal pain.